Hi Friends!
We are studying how to make solid lipid nanoparticles containing medicinal enzymes such as asparaginase and uricase. In this regard, there are some questions that I would like to ask for your guidance and advice.
According to the articles, methods such as double emulsion or solvent injection have been suggested for most pharmaceutical molecules. Are these methods suitable for medicinal enzymes (about 30-40 kilodaltons) or are other methods suggested?
If it is possible to use the mentioned methods, can the appropriate type of lipid and surfactant and organic solvent that has the most efficiency be determined?
In general, is there a specific criterion for determining the type of lipid and surfactant, as well as the SLN manufacturing method, to make solid lipid nanoparticles?
Hello Sajjad !
Solid lipid nanoparticles (SLNs) are promising carriers for loading drug enzymes due to their biocompatibility, ability to protect enzymatic activity, and controlled release properties. The synthesis of SLNs for enzyme delivery involves techniques such as hot or cold high-pressure homogenization, solvent emulsification-evaporation, microemulsion-based methods, or phase inversion techniques. The choice of method depends on the enzyme's stability, solubility, and encapsulation efficiency requirements.
Suitable lipids for SLN synthesis include biocompatible and biodegradable solid lipids such as glyceryl monostearate, glyceryl behenate, stearic acid, palmitic acid, and trimyristin. These lipids provide a solid matrix at body temperature, ensuring stability and controlled enzyme release. For enzyme stabilization, lipids with antioxidant properties (e.g., Compritol 888 ATO) may be used to minimize degradation.
The choice of surfactants is critical for stabilizing SLNs and maintaining enzyme activity. Commonly used surfactants include polysorbates (Tween 80), polyvinyl alcohol (PVA), lecithin, and Pluronic F68 or F127. These surfactants reduce interfacial tension and prevent aggregation, ensuring a uniform size distribution and stable nanoparticle system. The surfactant type and concentration must be optimized to avoid enzyme denaturation while achieving efficient encapsulation and sustained release.
Overall, selecting mild preparation techniques, lipids with enzyme-compatible melting points, and non-denaturing surfactants is essential for creating functional SLNs suitable for drug enzyme delivery.
Dear Mani
Indeed, thank you so much for great explanation of the issue and giving precise guidance regrading lipids and surfactants for SLN syntheis.
Actually your answer, is a good pluralization of most of the articles in this field and is highly appreciated.
Best Wishes
Sajjad
See this soures
https://link.springer.com/article/10.1007/s13346-023-01398-5
Dear Hezam
Thank you for the great link!
It is very helpful.
Best Wishes